Providence Capital Advisors, LLC Tg Therapeutics, Inc. Transaction History

Providence Capital Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	SELL	$10.23 - $19.34 $18,240 - $34,483	-1,783 Reduced 93.35%	127 $1,000
Q1 2023 May 17, 2023	BUY	$10.23 - $19.34 $19,498 - $36,862	1,906 Added 47650.0%	1,910 $28,000
Q1 2023 May 10, 2023	SELL	$10.23 - $19.34 $1,258 - $2,378	-123 Reduced 96.85%	4 $0
Q4 2022 Feb 07, 2023	BUY	$5.01 - $11.83 $636 - $1,502	127 New	127 $1,000

338

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Providence Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Providence Capital Advisors, LLC with notifications on news.